URD 2024
Category: Press release
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations
CTO Appointment
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine – Strong Outlook for 2025
2024 Annual Results
Transgene to Participate in Upcoming Investor Meetings
Investors meetings
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
Eligibility PEA-PME
Transgene To Participate in the Biomed Forum Investor Conference
BIOMED FORUM
Transgene Announces Financial Calendar for 2025
calendrier 2025
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
SITC 2024
Transgene Reports Business, Pipeline and Financial Update for Q3 2024
Financial Q3 2024
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment
ProBioGen